Rocket Pharmaceuticals Aligned With FDA on Continued Enrollment and Dosing and key elements of Phase 2 trial of RP-A501 for Danon disease
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,
Rocket Pharma and the FDA agree on how to test a new heart disease medicine. When companies and the FDA line up on testing plans, it shows smoother progress ahead.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.